Director Clinical Contracts
Vir Biotechnology
Director Clinical Contracts
Vir Biotechnology
Develops monoclonal antibodies for infectious diseases
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies.
Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
We believe the success of our colleagues drives the success of our mission. We are committed to creating a company where everyone feels supported and encouraged to give their best.
Vir Biotechnology is seeking a Director, Clinical Contracts-Transactional Counsel to lead the execution of clinical contracting activities supporting our global development programs. Reporting to the Vice President, Strategic Transactions, this role will serve as the primary legal and business partner for clinical contracting matters across clinical trial sites and external vendors.
This is a hands-on position responsible for personally managing the drafting, review, negotiation, and execution of a broad range of clinical agreements. The successful candidate will combine deep clinical contracting expertise with practical business judgment to support efficient study startup and execution while appropriately managing risk.
This role is based in our San Francisco headquarters with an expectation of 3 days per week in the office.
The expected salary range for this position is $203,500 to $284,000 per year. Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors.
Vir Biotechnology's compensation and benefits are aligned with the current market and commensurate with the person’s experience and qualifications. All full-time employees receive a package that includes compensation, bonus and equity as well as many other Vir Biotechnology benefits and perks such as health and welfare benefit plans, non-accrual paid time off, company shut down for holidays, commuter benefits, 401K match and lunch each day in the office.
Applicants must currently be authorized to work for any employer in the U.S. We are unable to sponsor or take over sponsorship of an employment Visa at this time.
All employment decisions at Vir Biotechnology are based on legitimate, non-discriminatory business requirements, job duties and individual qualifications. Employment decisions are made without regard to any legally protected characteristics.
This commitment extends to all management practices and decisions, including recruitment and hiring, compensation, appraisal systems, promotions, training and career development programs. Vir Biotechnology also strongly commits to providing employees with a work environment free of unlawful conduct or harassment.
Vir Biotechnology Human Resources leads recruitment and employment for Vir Biotechnology. Unsolicited resumes sent to the company from recruiters do not constitute any type of relationship between the recruiter and Vir Biotechnology and do not obligate us to pay fees should we hire from those resumes. We ask that external recruiters and/or agencies not contact or present candidates directly to our hiring manager or employees.
For hires based in the United States, Vir Biotechnology, participates in E-Verify.
Develops monoclonal antibodies for infectious diseases
Vir Biotechnology uses the immune system to treat infectious diseases by engineering monoclonal antibodies and exploring T cell vaccines, powered by an AI-assisted antibody discovery platform. Its therapies target diseases with high global impact, including hepatitis B, hepatitis delta, HIV, influenza, COVID-19, RSV/hMPMV, and HPV, with an investigational HIV T cell vaccine in development. Monoclonal antibodies specifically target viral proteins to block infection or mark pathogens for immune attack, while AI helps design and optimize these antibodies. The company differentiates itself through its combination of a proprietary mAb platform, AI/ML-enabled discovery, and broad, collaborative programs to accelerate development. Its goal is to transform lives by delivering therapies that address unmet patient needs and reduce the global burden of infectious diseases.
Explore more opportunities at Vir Biotechnology